The global Spasticity Treatment Market is worth US$ 13.1 Billion as of now and is expected to reach US$ 28.4 Billion by the year 2033 at a CAGR of 8.1% between 2023 and 2033. Spasticity is turning out ...

The global neurological device company, Codman & Shurtleff, Inc. (Codman) has received the US Food and Drug Administration (FDA) approval through a PMA supplement for its Medstream Programmable ...